Table 1 Pathological classification for DLBCL patients.
From: Immune signature and pathways investigation of adrenal gland diffuse large B-cell lymphoma
Patient | Pathological molecular classification | Pathologic |
|---|---|---|
Patient1 | BCL2+, CD20+, CD21+, cMyc > 30%, Ki67 > 90%, MUM1+, PAX5+ | Non-GCB DLBCL |
Patient2 | BCL2+, CD20+, Ki67 > 80%, MUM1+, PAX5+ | Non-GCB DLBCL |
Patient3 | BCL2+, BCL6+, CD20+, CD79a+, CD3+, Ki67 > 75%, MUM1+, PAX5+ | Non-GCB DLBCL |
Patient4 | BCL2+, BCL6+, CD20+, VIM+, Ki67 > 80%, MUM1+ | Non-GCB DLBCL |
Patient5 | CD2+, CD20+, CD79a+, Ki67 > 85% | Non-GCB DLBCL |
Patient6 | BCL6+, CD20+, LCA+, Ki67 > 90%, MUM1+, VIM+ | Non-GCB DLBCL |
Patient7 | BCL2+, CD20+, PAX5+, CD79a+, LCA+, Ki67 > 90%, MUM1+ | Non-GCB DLBCL |
Patient8 | BCL2+, BCL6+, CD20+, LCA+, CD3+, CD5+, CD7+, Ki67 > 67%, MUM1+ | Non-GCB DLBCL |
Patient9 | BCL2+, BCL6+, CD20+, CD3+, CD30+, Ki67 > 90%, MUM1+, TP53+ | Non-GCB DLBCL |
Patient10 | BCL2+, CD20+, Ki67 > 80%, MUM1+ | Non-GCB DLBCL |
